JP2008500399A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500399A5
JP2008500399A5 JP2007527564A JP2007527564A JP2008500399A5 JP 2008500399 A5 JP2008500399 A5 JP 2008500399A5 JP 2007527564 A JP2007527564 A JP 2007527564A JP 2007527564 A JP2007527564 A JP 2007527564A JP 2008500399 A5 JP2008500399 A5 JP 2008500399A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
protein
nucleic acid
heterologous nucleic
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007527564A
Other languages
English (en)
Japanese (ja)
Other versions
JP4896021B2 (ja
JP2008500399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018225 external-priority patent/WO2006078294A2/en
Publication of JP2008500399A publication Critical patent/JP2008500399A/ja
Publication of JP2008500399A5 publication Critical patent/JP2008500399A5/ja
Application granted granted Critical
Publication of JP4896021B2 publication Critical patent/JP4896021B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007527564A 2004-05-21 2005-05-20 呼吸器系病原体ワクチンのためのアルファウイルスベクター Expired - Lifetime JP4896021B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57343304P 2004-05-21 2004-05-21
US60/573,433 2004-05-21
US64373705P 2005-01-12 2005-01-12
US60/643,737 2005-01-12
PCT/US2005/018225 WO2006078294A2 (en) 2004-05-21 2005-05-20 Alphavirus vectors for respiratory pathogen vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008125258A Division JP2008266341A (ja) 2004-05-21 2008-05-12 呼吸器系病原体ワクチンのためのアルファウイルスベクター

Publications (3)

Publication Number Publication Date
JP2008500399A JP2008500399A (ja) 2008-01-10
JP2008500399A5 true JP2008500399A5 (enExample) 2008-06-26
JP4896021B2 JP4896021B2 (ja) 2012-03-14

Family

ID=36692669

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527564A Expired - Lifetime JP4896021B2 (ja) 2004-05-21 2005-05-20 呼吸器系病原体ワクチンのためのアルファウイルスベクター
JP2008125258A Pending JP2008266341A (ja) 2004-05-21 2008-05-12 呼吸器系病原体ワクチンのためのアルファウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008125258A Pending JP2008266341A (ja) 2004-05-21 2008-05-12 呼吸器系病原体ワクチンのためのアルファウイルスベクター

Country Status (6)

Country Link
US (3) US20090104226A1 (enExample)
EP (3) EP1766034B1 (enExample)
JP (2) JP4896021B2 (enExample)
CA (1) CA2567446C (enExample)
ES (1) ES2647491T3 (enExample)
WO (1) WO2006078294A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2526196T3 (es) * 2004-05-25 2015-01-08 Novartis Vaccines And Diagnostics, Inc. Constructos de encapsidación de replicones de alfavirus
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
RS54489B1 (sr) * 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
HRP20221048T1 (hr) 2010-08-31 2022-11-11 Glaxosmithkline Biologicals Sa Mali liposomi za isporuku rna koja kodira imunogen
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
PH12013502442A1 (en) * 2011-05-26 2018-03-21 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP3998064A1 (en) 2011-06-08 2022-05-18 Translate Bio, Inc. Cleavable lipids
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US20140255472A1 (en) * 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
AU2012322704B2 (en) * 2011-10-11 2017-09-07 Novartis Ag Recombinant self-replicating polycistronic RNA molecules
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
JP6364007B2 (ja) * 2012-08-17 2018-07-25 インターベット インターナショナル ベー． フェー． 不活化レプトスピラ細菌の免疫原性組成物
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
JP6983665B2 (ja) * 2015-06-12 2021-12-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
AU2016302237B2 (en) 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
WO2017123652A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
EP4691484A2 (en) * 2016-05-04 2026-02-11 CureVac SE Influenza mrna vaccines
MA50335A (fr) * 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
WO2018147802A1 (en) * 2017-02-07 2018-08-16 Agency For Science, Technology And Research Alphavirus nsp mutants as vaccines
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
JP7346417B2 (ja) * 2017-12-18 2023-09-19 インターベット インターナショナル ベー． フェー． ブタインフルエンザａウイルスワクチン
CA3085975A1 (en) 2017-12-20 2019-06-27 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen constructs
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US12331076B2 (en) * 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
EP3877531A4 (en) * 2018-11-07 2022-08-31 Gritstone bio, Inc. ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
IT202000009625A1 (it) * 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.
WO2021228731A1 (en) 2020-05-11 2021-11-18 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
CN116322758A (zh) * 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
WO2021255225A1 (en) * 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
US20230277649A1 (en) * 2020-06-19 2023-09-07 Intervet Inc. Swine influenza a virus vaccine comprising two distinct rna replicon particles
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
WO2022049276A1 (en) * 2020-09-07 2022-03-10 Intervet International B.V. Ha stem vaccine for ha antibody-positive targets
WO2022087006A1 (en) * 2020-10-20 2022-04-28 George Mason Research Foundation, Inc. Hybrid alphavirus-sars-cov-2 particle and methodology of making and using same
JP2023549787A (ja) 2020-11-12 2023-11-29 インターベット インターナショナル ベー． フェー． キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
CA3199996A1 (en) * 2020-12-02 2022-06-09 Pirada ALLEN Multicistronic rna vaccines and uses thereof
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CN117279660A (zh) * 2021-01-19 2023-12-22 磨石生物公司 经修饰的甲病毒载体
CN112899301B (zh) * 2021-01-29 2023-04-11 中国热带农业科学院热带生物技术研究所 一种木薯普通花叶病毒诱导的基因沉默系统及其应用
US20220249651A1 (en) * 2021-02-01 2022-08-11 Aegle Biotech Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection
US20220401548A1 (en) * 2021-06-17 2022-12-22 National Yang Ming Chiao Tung University Sindbis virus dna-based vaccine
JP2024545253A (ja) * 2021-12-17 2024-12-05 ＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｊａｐａｎ株式会社 効率的なワクチン
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP1997900A3 (en) 1996-04-05 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5842723A (en) 1996-11-25 1998-12-01 Burex Automotive America, Inc. Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US20030180257A1 (en) 1997-11-14 2003-09-25 Mark Parrington Alphavirus vectors for paramyxovirus vaccines
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000018929A2 (en) * 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
ATE465266T1 (de) 1998-12-31 2010-05-15 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
WO2000061772A2 (en) 1999-04-14 2000-10-19 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AU2001249380A1 (en) * 2000-03-22 2001-11-07 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CN100489107C (zh) * 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
BRPI0111830B8 (pt) * 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
ATE499948T1 (de) 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
WO2004000872A2 (en) * 2002-06-21 2003-12-31 University Of North Carolina At Chapel Hill Improved alphavirus vectors having attenuated virion structural proteins
JP4991108B2 (ja) * 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
CN1791678A (zh) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
DK1629004T3 (da) * 2003-06-05 2008-11-17 Wyeth Corp Immunogene sammensætninger indeholdende venezuelansk hesteencephalitisvirus-replikonvektorer og paramyxovirus-proteinantigener
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus

Similar Documents

Publication Publication Date Title
JP2008500399A5 (enExample)
US20240075125A1 (en) Expression systems
CN108348593B (zh) 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
Denis et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform
Levi et al. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection
WO2003072719A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
JP2007505033A5 (enExample)
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
JP2014507146A5 (enExample)
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
JP5675789B2 (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
CA2835967A1 (en) Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
CN103228293A (zh) 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂
CN101899461B (zh) 一种编码甲型流感病毒NP蛋白和M2e多肽的融合基因
Tomčíková et al. Different mechanisms of the protection against influenza A infection mediated by broadly reactive HA2-specific antibodies
US20160120974A1 (en) Semi-live respiratory syncytial virus vaccine
CN107961371A (zh) 季节流感-rsv联合疫苗及其制备方法和应用
Hnuma et al. Characteristics of Cytotoxic T Lymphocytes Directed to Influenza Virus Haemagglutinin Elicited by Immunization with Muramyldipeptide‐Influenza Liposome Vaccine
US20160346378A1 (en) Semi-live respiratory syncytial virus vaccine
JP7651129B2 (ja) ウイルスの非構造タンパク質が担持された複合タンパク質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン
KR20240011134A (ko) Rsv 및 piv3 감염을 예방하기 위한 조성물 및 방법